|
 "In order to get on the (product lists), which receive subsidies by
the different insurance companies, we need to offer rebates," Mike
Rulis, senior vice president of corporate communications told
Reuters.
"Those rebates have increased over the years, as well as list
prices."
The world's largest insulin maker gets around half its revenue in
the United States, but prices have been squeezed by pharmacy benefit
managers (PBMs) who administer drug benefits and negotiate rebates
for employers and health plans.
U.S. Senator Bernie Sanders and Representative Elijah Cummings
called on antitrust regulators on Thursday to investigate whether
insulin and diabetes drugs makers such as Sanofi SA, Eli Lilly and
Co and Novo Nordisk have colluded to set drug prices on the U.S.
market.
Last year Novo Nordisk offered an average rebate of 55 percent on
its products in the United States, Rulis told Reuters, but could not
elaborate further due to trade confidentiality.
Some U.S. consumers have experienced price increases, while others
have not, he said.
[to top of second column] |
Novo Nordisk shares were down 3.0 percent at 1047 GMT on the
Copenhagen main index.
(Reporting by Jacob Gronholt-Pedersen; writing by Nikolaj Skydsgaard;
editing by Jason Neely)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
